Zealand Pharma Reports Strong Q4 2025 Results Driven by Roche Partnership

Zealand Pharma reported its Q4 2025 earnings, showcasing robust financial performance driven by significant revenue gains from its partnership with Roche. The company's full-year 2025 revenue reached DKK 9.2 billion, largely driven by a substantial upfront payment from Roche, while net operating expenses remained within the guidance range at DKK 2.1 billion.

The company reported a net positive result of DKK 6.5 billion for the full year and ended 2025 with a cash position of DKK 15.1 billion. Research and development accounted for 76% of expenses, underscoring the company's commitment to innovation.

Despite the strong financial results, Zealand Pharma's stock price decreased by 2.16% in pre-market trading. The stock's last close was at 391.05, with a 52-week range between 307.1 and 770.

Zealand Pharma has set its 2026 operating expense guidance between DKK 2.72 billion and DKK 3.3 billion. The company anticipates potential milestone payments from Roche totaling $700 million in 2026.

The CEO highlighted the company's focus on delivering patient-desired weight loss and its commitment to innovation. "The key to unlock the value in this market is to develop therapies that provide patients with the weight loss they're looking for," he stated. The CEO also emphasized the company's goal to advance over 10 candidates into the clinic in the next five years.

The company's strategic partnerships, particularly with Roche and Boehringer Ingelheim, have positioned it well in the competitive obesity treatment market. Zealand Pharma is planning to advance more than 10 clinical candidates over the next five years, emphasizing its commitment to expanding its pipeline.

During the earnings call, leadership reiterated their focus on patient-desired outcomes and the potential of their KV1.3 channel blocker in treating autoimmune conditions.